Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Tax Provisions: 2017-2024

Historic Tax Provisions for Corcept Therapeutics (CORT) over the last 8 years, with Dec 2024 value amounting to $20.3 million.

  • Corcept Therapeutics' Tax Provisions fell 177.23% to -$4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.7 million, marking a year-over-year decrease of 172.16%. This contributed to the annual value of $20.3 million for FY2024, which is 10.14% up from last year.
  • Per Corcept Therapeutics' latest filing, its Tax Provisions stood at $20.3 million for FY2024, which was up 10.14% from $18.4 million recorded in FY2023.
  • Corcept Therapeutics' 5-year Tax Provisions high stood at $25.6 million for FY2020, and its period low was $12.5 million during FY2021.
  • For the 3-year period, Corcept Therapeutics' Tax Provisions averaged around $17.8 million, with its median value being $18.4 million (2023).
  • In the last 5 years, Corcept Therapeutics' Tax Provisions slumped by 51.18% in 2021 and then grew by 24.67% in 2023.
  • Over the past 5 years, Corcept Therapeutics' Tax Provisions (Yearly) stood at $25.6 million in 2020, then plummeted by 51.18% to $12.5 million in 2021, then grew by 18.24% to $14.8 million in 2022, then increased by 24.67% to $18.4 million in 2023, then grew by 10.14% to $20.3 million in 2024.